FGA139

FGA139 is a cysteine proteases inhibitor with IC50 values of 4.98/3.14 μM for cathepsin B/L. FGA139 reduces LPS-induced NO production in RAW264.7 cells and tumor necrosis factor (TNFα) levels in microglia, and has anti-oxidative stress and anti-inflammatory activities. FGA139 promotes the secretion of neuroprotective metabolites purine and linoleic acid by LPS-stimulated microglia. FGA139 can be used in neuroinflammatory diseases research[1].

Product Specifications

UNSPSC

12352211

Target

Cathepsin; NO Synthase; TNF Receptor

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease

Field of Research

Inflammation/Immunology; Neurological Disease

Smiles

O=C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CC(C)C)C(/C=C/C(OCC)=O)=O)=O)[C@@H](N2N=NC(CCCCC3=C4[N+]([B-](F)(F)N5C3=C(C)C=C5C)=C(C)C=C4C)=C2)CC6=CC=CC=C6

Molecular Formula

C48H58BF2N7O5

Molecular Weight

861.83

References & Citations

[1]Canseco-Rodriguez A, et al. FGA139, a Novel Cysteine Protease Inhibitor, Exhibits Anti-Inflammatory and Neuroprotective Activity and Reveals Microglial Modulation via Multi-Omics Profiling[J]. bioRxiv, 2025: 2025.05. 03.652036.|[2]Agost-Beltrán L, et al. Profiling Cysteine Proteases Activities in Neuroinflammatory Cells. ChemMedChem. 2025 Feb 1;20 (3) :e202400520.